Jonathan M. Meyer - Concepedia

Author

Jonathan M. Meyer

University of California San Diego

Also Known As

J M Meyer, J. Meyer, Jonathan M Meyer, Jonathan M. Meyer

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

University of California San Diego IQVIA (United States)Duke University Columbia University University of Cincinnati

About

Jonathan M. Meyer is an author at University of California San Diego specializing in medicine, psychiatry, and schizophrenia.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	1.9K
2	Social Sciences	5	5	1.6K
3	Epidemiology	2	2	237
4	Public Health	1	1	15
5	Global Health	1	1	1.1K

Jonathan M. Meyer

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III Joseph P. McEvoy, Jonathan M. Meyer, Donald Goff, Schizophrenia Research Intervention EffectivenessMetabolic SyndromeMetabolic DisorderPsychiatryPsychotic Disorder	2005	1.1K
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1 Jonathan M. Meyer, Vicki G. Davis, Donald Goff, Schizophrenia Research Catie Schizophrenia TrialMetabolic SyndromePsychiatryPsychotic DisorderPsychotropic Medication	2008	285
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study Gail L. Daumit, Donald Goff, Jonathan M. Meyer, Schizophrenia Research Risk PredictionPsychiatryPsychotic DisorderSchizophreniaAntipsychotic Effects	2008	222
Inflammatory Markers in Schizophrenia: Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study Jonathan M. Meyer, Joseph P. McEvoy, Vicki G. Davis, Biological Psychiatry PsychiatryPsychotic DisorderPsychotropic MedicationClinical TrialsPsychopharmacology	2009	108
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1 Jonathan M. Meyer, Vicki G. Davis, Joseph P. McEvoy, Schizophrenia Research Antipsychotic TreatmentPsychiatryPsychotic DisorderMedicinePsychopharmacology	2008	74
From chlorpromazine to olanzapine: a brief history of antipsychotics Jonathan M. Meyer, G. M. Simpson Psychiatric Services Psychoactive DrugPsychiatryMedicinePsychotropic MedicationPsychopharmacology	1997	40
The concomitant use of second-generation antipsychotics and long-term antiretroviral therapy may be associated with increased cardiovascular risk Maria Ferrara, Anya Umlauf, Chelsea Sanders, Psychiatry Research PsychiatryCardiovascular DiseasePsychotropic MedicationTreatment And PreventionPsychopharmacology	2014	15

Page 1